XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1
SEGMENT INFORMATION
 9 Months Ended
Jul. 31, 2024
Segment Reporting [Abstract]  
SEGMENT INFORMATION

11. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in three reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines and (iii) Other. The following represents selected financial information for our segments for the three and nine months ended July 31, 2024 and 2023 and as of July 31, 2024 and October 31, 2023, in thousands:

 

                 
   For the Three Months Ended
July 31,		   For the Nine Months Ended
July 31,		 
   2024   2023   2024   2023 
Net loss:                    
CAR-T Therapeutics  $(1,145)  $(1,091)  $(4,115)  $(2,999)
Cancer Vaccines   (2,160)   (1,390)   (5,628)   (3,261)
Other   (10)   (67)   (42)   (949)
Total  $(3,315)  $(2,548)  $(9,785)  $(7,209)
                     
Total operating costs and expenses  $3,592   $2,844   $10,668   $8,170 
Less non-cash stock-based compensation   (1,179)   (1,217)   (3,699)   (3,507)
Operating costs and expenses excluding non-cash stock-based compensation  $2,413   $1,627   $6,969   $4,663 
Operating costs and expenses excluding non-cash stock-based compensation:                    
CAR-T Therapeutics  $789   $713   $2,943   $1,930 
Cancer Vaccines   1,614    855    3,988    1,966 
Other   10    59    38    767 
Total  $2,413   $1,627   $6,969   $4,663 

 

   July 31,
2024		   October 31,
2023		 
Total assets:          
CAR-T Therapeutics  $7,493   $7,523 
Cancer Vaccines   15,290    17,215 
Other   125    784 
Total  $22,908   $25,522 

 

Operating costs and expenses excluding non-cash stock-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

 

The Company’s consolidated revenue of $210,000 and inventor royalties, contingent legal fees, litigation and licensing expense of $161,000 for the nine months ended July 31, 2023 were solely related to our encrypted audio/video conference calling technology, which is included in our Other segment. All our revenue is generated domestically (United States) based on the country in which the licensee is located.